Objectives: To investigate the predictive value of various molecular forms of prostatespecific antigen in men with baseline prostate-specific antigen <2.0 ng/mL. Methods: The case cohort comprised 150 men with a baseline prostate-specific antigen level <2.0 ng/mL, and who developed prostate cancer within 10 years. The control cohort was 300 baseline prostate-specific antigen-and age-adjusted men who did not develop prostate cancer. Serum prostate-specific antigen, free prostate-specific antigen, and [À2] proenzyme prostate-specific antigen were measured at baseline and last screening visit. The predictive impact of baseline prostate-specific antigen-and [À2] proenzyme prostate-specific antigen-related indices on developing prostate cancer was investigated. The predictive impact of those indices at last screening visit and velocities from baseline to final screening on tumor aggressiveness were also investigated. Results: The baseline free to total prostate-specific antigen ratio was a significant predictor of prostate cancer development. The odds ratio was 6.08 in the lowest quintile baseline free to total prostate-specific antigen ratio subgroup. No serum indices at diagnosis were associated with tumor aggressiveness. The Prostate Health Index velocity and [À2] proenzyme prostate-specific antigen/free prostate-specific antigen velocity significantly increased in patients with higher risk D'Amico risk groups and higher Gleason scores. Conclusions: Free to total prostate-specific antigen ratio in men with low baseline prostate-specific antigen levels seems to predict the risk of developing prostate cancer, and it could be useful for a more effective individualized screening system. Longitudinal changes in [À2] proenzyme prostate-specific antigen-related indices seem to correlate with tumor aggressiveness, and they could be used as prognostic tool before treatment and during active surveillance.
Introduction
The incidence of PCa has increased in developed Western 1 and Asian countries. 2 Reliable randomized studies have confirmed that PSA-based screening every 2 or 4 years in men aged 50-74 years significantly decreases the risk of death as a result of PCa. 3, 4 The controversy regarding PCa screening has shifted from a mortality issue to minimizing the risk of overdetection and overtreatment. Uniform screening intervals, as well as uniform recruitment of elderly men, are not ideal from a cost-effectiveness perspective.
Several studies have shown that baseline PSA level is useful to objectively predict the development of PCa, and could be key for establishing an internationally standardized, optimal screening system. [5] [6] [7] [8] A recent nested case-control study showed that targeted PSA screening of men with a PSA level >2.0 ng/mL at the age of 60 years effectively and significantly reduces the risk of death as a result of PCa. 9 However, death as a result of PCa was not different between a screening and control cohort with PSA levels <2.0 ng/mL at the age of 60 years. In contrast, the Prostate Cancer Prevention Trial showed that the prevalence of PCa was unexpectedly high, at 12.4% in men with PSA levels <2.0 ng/mL. healthy men with a PSA level <2.0 ng/mL. In the present retrospective case-control study, we investigated the predictive impact of various baseline serum free PSA-and p2PSA-related indices on developing PCa in men with a baseline PSA level <2.0 ng/mL, and also investigated the relationship of those indices at the final screen visit and those kinetics from baseline to final screen visit with tumor aggressiveness in men diagnosed with PCa.
Methods
The scheme of the present retrospective nested case-control study that used a screening database and the Gunma University serum bank, and flow sheet of patient enrollment is shown in Figure 1 . The primary aim was to investigate predictive impacts of baseline %f-PSA and p2PSA-related indices on development of PCa in the period that men did not have suspicious findings on PSA. The case cohort was 150 men with a baseline PSA level <2.0 ng/mL and who subsequently developed PCa within 10 years from the baseline screening. The biopsy trigger was above the age-specific PSA cut-off values (3.0 ng/mL for age <65 years, 3.5 ng/mL between 65-69 years and 4.0 ng/mL for ≥70 years). The median number of biopsy cores was 11, and the range was 5-21 (IQR [8] [9] [10] [11] [12] .
The control cohort included 300 baseline PSA-and ageadjusted men who did not develop PCa within almost the same follow-up period for each corresponding man in the case cohort. Differences in baseline PSA levels, age, and screening intervals between candidates for the control group and each corresponding man in the case group were within 0.2 ng/mL, 1 year-old and 1 year, respectively. Two men were selected for the control cohort as against one man in the case cohort. The other inclusion criteria for the control group were men with a PSA level <4.0 ng/mL at the last screening visit, and lower PSAV from baseline to final screening, which might represent a very low risk for developing clinically manifested PCa in the future. 14 The second aim of the present study was to investigate the predictive impact of PSA level, %f-PSA, and p2PSA-related indices at the final screening and those velocities between the baseline and final screenings on tumor aggressiveness in terms of the risk classification proposed by D'Amico and the biopsy GS. Clinicopathological data, including digital rectal examination findings, transrectal ultrasonography findings, GS, and clinical stage were investigated in patients who visited 26 affiliated general hospitals and urological clinics.
Whole blood samples were stored at 4°C, typically centrifuged and separated into serum within 3 h, and stored at À70°C. All serum PSA levels in the actual screening in Gunma Prefecture were determined using the E-test Tosoh II PSA assay (Tosoh, Tokyo, Japan). Therefore, all frozen serum samples were re-analyzed for total PSA level, and free PSA and p2PSA levels by the Access Hybritech assay (Beckman Coulter, Brea, CA, USA) using the UniCel DxI800 instrument (Beckman Coulter) at Mishima Laboratory, Shizuoka, Japan. Investigated indices were total PSA, %f-PSA, %p2PSA, p2PSA/%f-PSA and the PHI, which is calculated as p2PSA / free PSA 9 √PSA, at baseline and last screenings. PSAV, %f-PSA velocity, PHI velocity, %p2PSA velocity and p2PSA/%f-PSA velocity, from baseline to last screening, were also calculated. In the case cohort, relationships of those indices and velocities with risk classification and GS were investigated.
The present study was approved by the ethics committee of the Gunma University School of Medicine (approval number: 13-56). Statistical comparisons between the serum indices were carried out using the Mann-Whitney U-test. All statistics and AUC-ROC calculations were carried out using SPSS version 24 (IBM, Armonk, NY, USA).
Results
Serum PSA, free PSA-related and p2PSA-related indices, and the kinetics from the baseline to final screening visit and screening interval in the case and control cohorts are shown in Table 1 . Baseline PSA levels were significantly different between the case and control cohorts, despite adjustment within 0.2 ng/mL at the participants' enrollment, but the difference in median baseline PSA was small at 0.11 ng/mL. Baseline %f-PSA was significantly lower in the case versus control cohort (P = 0.0004). None of the baseline p2PSA-related indices could distinguish men that developed PCa (case cohort) from those did not (control cohort). Table 2 shows the odds ratios of developing PCa, calculated by dividing the total cohort by each of the baseline index. The %f-PSA distribution in the case and control cohorts was significantly different, and the risk of developing PCa in men with baseline %f-PSA below the median value was 2.8-fold higher than that of those above the median. None of the baseline p2PSA-related indices differentiated men who did versus did not develop PCa.
The predictive impact of baseline %f-PSA was further investigated by dividing the total cohort into tertiles, quartiles and quintiles (Table 3 ). The risk of developing PCa within several years was significantly higher in the subgroup with a lower %f-PSA when the highest %f-PSA subgroup was taken as a reference, except when the second-highest %f-PSA subgroup was divided into quartiles and quintiles. The odds ratios were 4.00, 4.87, and 6.08 in the lowest baseline %f-PSA subgroup for the tertile, quartile and quintile groupings, respectively.
The clinicopathological features of 150 patients diagnosed with PCa was clinically localized disease in 87.4%, locally advanced disease in 11.2% and metastatic disease in 1.4%. The percentage of positive biopsy cores in total cores was <25% in 67.9%, 26-50% in 27.9% and >50% in 4.2%. The GS was 6 in 18.5%, 7 (3 + 4) in 25.9%, 7 (4 + 3) in 23.0%, 8 in 23.0% and 9-10 in 9.6%. According to the D'Amico risk classification, 14.2%, 43.3%, and 42.5% was the lowrisk, intermediate-risk and high-risk group, respectively. There were some unknown cases in clinical stage (n = 7), in GS (n = 15) and in D'Amico risk classification (n = 16). The levels of serum indices at final screening and velocities from baseline to final screening according to D'Amico risk group are shown in Table 4 . None of the serum indices at diagnosis were different among the risk groups. PSAV was significantly different only between the low-and high-risk groups. %f- Men who underwent prostate biopsy with increasing PSA within 10 years n = 620
Men diagnosed with prostate cancer (final candidates for the case group) n = 267
Men who did not develop prostate cancer within 10 years n = 34 528
Men who did not increase PSA above 4 ng/mL at the final screening n = 33 541 Fig. 1 Scheme of the case-control study and patient enrollment.
PSA velocity was significantly lower in the high risk group versus the combined low-and intermediate-risk group. p2PSA-related kinetics differentiated the risk groups most accurately, and %p2PSA velocity was the best marker to distinguish between the risk groups. The levels of serum indices at final screening and velocities from baseline to final screening according to the GS are also shown in Table 4 . None of the serum indices at diagnosis were different among any of the GS subgroups. PSAV was significantly lower in patients with a GS of 6 versus those with a GS of 3 + 4, or GS 8-10. However, the absolute PSAV value did not increase steadily with the GS. %f-PSA velocity was significantly lower in patients with a GS of 8-10 than those with a GS of 6. However, the absolute value of %f-PSA in patients with a GS of 4 + 3 was higher compared with those with a GS of 6, or with a GS of 3 + 4. In contrast, p2PSA/%f-PSA velocity differentiated patients with a GS of 6 from those with a GS of 7 or 8. Furthermore, PHI velocity and %p2PSA velocity differentiated patients with different GSs more accurately. PHI increased significantly with GS, and %p2PSA velocity increased in the order of GSs for cancer of 3 + 4, 4 + 3 and 8-10.
The AUC-ROCs of the serum indices, and velocities according to subgroup of the D'Amico risk classifications and GS are shown in Table 5 . No differences or trends were observed in the AUC-ROCs among serum indices at the final screening visit. No differences in the AUC-ROC were observed in the kinetics. However, the largest AUC-ROC in each comparison was seen for PHI velocity or %p2PSA velocity.
Discussion
The latest results from the ERSPC showed a significant decrease in mortality from prostate cancer. 3 In contrast, the Prostate, Lung, Colorectal and Ovarian screening study 15 failed as a randomized controlled trial because of serious and uncontrollable contamination in the control cohort. 16 Therefore, controversies in PSA screening have already shifted from the mortality issue to overdetection and overtreatment issues. The number required to invite to PSA screening and the number required to detect PCa to avert one PCa death was 781 and 27, respectively, during the 13-year median follow up in the ERSPC. 3 An optimal PSA screening system needs to be established to minimize overdetection, overtreatment and reduction in quality of life due to treatment. Establishing a tailor-made screening system could minimize these drawbacks and improve cost-effectiveness.
Several studies have shown that baseline PSA level is key for establishing an individualized and internationally standardized screening system. [5] [6] [7] [8] [9] 17 In men with a baseline PSA <1.0 ng/mL, it might be possible to prolong the screening interval without delaying the detection of clinically significant PCa. The optimal screening interval in men with a baseline PSA of 1.0-2.0 ng/mL is uncertain. However, a retrospective nested case-control study showed that the risk of developing potentially lethal PCa decreased in a screening cohort during the 15-year follow up, particularly in men with a baseline PSA >2.0 ng/mL at the age of 60 years. 9 The risk of developing lethal PCa in men with a baseline PSA <2.0 ng/mL at the age of 60 years might be the same between men recommended for biannual PSA screening and those who are followed up with routine medical care. In contrast, Candas et al. showed that the 5-year cumulative probability of detecting PCa in men with a baseline PSA <1.5 ng/ mL was 0.8%, which increased to 1.3% in men with a PSA of 1.5-2.0 ng/mL. 7 Sawada et al. showed that the cumulative probabilities of an increase in PSA >2.0 ng/mL over 10 years were 7.7%, 18.3%, 57.3%, and 88.7% in men with a baseline PSA of 0.0-0.5, 0.6-1.0, 1.1-1.5 and 1.6-2.0 ng/ mL, respectively. 18 Therefore, identifying men at risk for developing PCa is important, even if their baseline PSA is <2.0 ng/mL.
The predictive impact of %f-PSA on developing PCa has only been investigated in a few studies. The Finnish section of the ERSPC investigated the cumulative risk of developing PCa in men with a PSA <3.0 ng/mL as a function of %f-PSA during a median 5.8-year follow up. 11 Men with a %f-PSA in the lowest quartile (<14.2%) showed a 6.9-fold increased risk compared with those with a %f-PSA in the highest quartile (>23.7%). A Japanese screening cohort, in which all participants had both total PSA and %f-PSA measured during screening, assessed the impact of %f-PSA on the risk of developing PCa in 6368 men with a PSA ≤4.0 ng/ mL during a median 36-month follow up. 12 The risk of developing PCa in men with the lowest quartile of %f-PSA (<13.3%) was 21.2-fold higher than that in men with %f-PSA in the highest quartile (>22.2%). In the present study, the risk of developing PCa increased when baseline %f-PSA was lower, even with a baseline PSA <2.0 ng/mL. A strength of the present study was adjustment of well-known very strong predictive factors, baseline PSA and age, between the case and control groups. In particular, the baseline PSA adjustment could be a key issue in carrying out a case-control study investigating predictive markers for developing PCa. In contrast, distribution of %f-PSA in the PSA <2.0 ng/ mL within the actual screening is uncertain in the present retrospective study. Therefore, a prospective study would be necessary to clarify an absolute impact of %f-PSA on developing prostate cancer in men with baseline <2.0 ng/mL. Furthermore, if we investigate the impact of %f-PSA on the developing clinically significant PCa, it would be possible to propose more individualized screening intervals in the future. At the same time, the cost-effectiveness issue should be carefully discussed before updating an individualized screening system stratified by not only baseline PSA, but also %f-PSA.
One previous study showed a significant difference in p2PSA between men who developed PCa and those who did not 1-4 years before the final diagnosis. 13 However, mean baseline PSA levels 4 years before the final diagnosis were relatively high compared with those in the present study, and differed between men who developed PCa (3.5 ng/mL) and those who did not (2.8 ng/mL). In the present study, subgroup analyses of men who developed PCa within 3 and 5 years after the baseline screening did not show any predictive value of the p2PSA-related indices (data not shown). Therefore, the predictive impact of p2PSA-related indices on developing PCa might be limited to the very early preclinical stage of PCa. Several studies have shown a positive correlation between tumor aggressiveness and p2PSA-related indices. The GS increased with increasing p2PSA-related indices in men with PCa and PSA levels of 0.29-18.24 ng/mL. 19 Stephan et al. showed that the percentage of positive biopsies increased with increasing PHI, and that the percentage of patients with a GS ≥7 increased with PHI. 20 Catalona et al. also detected a positive correlation between PHI and the percentage of patients with a GS ≥7. 21 Our previous study using a Japanese cohort showed a positive relationship between p2PSA-related indices, GS and tumor length in biopsy specimens. 22 The present study using patients with PCa diagnosed in an early detection program did not observe an association between tumor aggressiveness and any of PSA-related indices at the final screening visit. This could be due to the inclusion of men with earlystage PCa and a low median PSA level of 4.73 ng/mL.
In the present case-control study, the kinetics of p2PSA-related indices were significantly related with tumor aggressiveness. However, it might not be acceptable to measure baseline p2PSA in all participants in the population-based screening because of the high cost and instability of p2PSA. 23 One promising option might be measuring p2PSA for men participating in private screening with an adequate cost setting. The other realistic option would be checking p2PSA in urological clinics for men suspicious for PCa due to a slightly higher PSA at the screening, and follow changes in p2PSA-related indices if men would refuse or would not be recommended immediate prostate biopsy due to any medical judgement. Those men would be able to check the kinetics of p2PSA-related indices before detecting PCa, and would have additional useful information on the aggressiveness of PCa before selecting treatment strategies.
A limitation of retrospective studies that use serum samples regards the stability of PSA-related derivatives. One study showed feasible stability of free PSA in whole blood and serum under various storage conditions. 23 The long-term stability of free PSA and p2PSA in serum stored at À70°C is uncertain, but the risk of degradation of PSA derivatives might be identical between the case and control cohorts.
The small sample size, especially in less aggressive cancer, might be a limitation in the present study. However, the kinetics of p2PSA-related indices could differentiate patients with GS 6 from those with GS 7-10, and the low-risk group from the intermediate-to high-risk group despite a small sample size. Those significant results could be due to the high potential of kinetics of p2PSA-related indices and a statistical power was enough for investigation. In contrast, some other indices or kinetics that might be of moderate potential to distinguish high aggressive cancer from low aggressive cancer might have a likelihood of misleading the significance because of the small sample size. Therefore, additional large studies would be necessary to conclude the predictive impact of various p2PSA-related indices on existing clinically significant PCa.
The other limitation of the present study was the reliability of the tumor aggressiveness evaluation based on the D'Amico risk classification and GS. However, the treatment strategies for patients with early-stage PCa varied, and only patients who underwent surgery had a final pathological diagnosis. Therefore, investigating the predictive impact of pretreatment biomarkers on long-term oncological outcomes after active surveillance and definitive treatment is required. Despite these limitations, the present retrospective study found that p2PSA-related kinetics were significantly correlated with tumor aggressiveness. A future prospective study should investigate whether this finding affects treatment indications for men proceeding to radiation therapy, and the active surveillance follow-up strategy, because those patients must be followed based only on pretreatment clinicopathological findings, which might be limited compared with patients who undergo surgery and receive final pathological evaluations.
In conclusion, %f-PSA in men with a PSA level <2.0 ng/ mL might be suitable for identifying those at high risk for developing PCa, and longitudinal changes in p2PSA-related indices might be useful markers for predicting tumor aggressiveness before treatment or during active surveillance. These indices and kinetics could be useful to establish a more effective, individualized screening system.
